Evidence map›Paper›PMID 34453193›Full record

ArticleCancer immunology, immunotherapy : CII2022

Correction to: Chemotherapy: a double‑edged sword in cancer treatment.

Nafiseh Behranvand, Farzad Nasri, Reza Zolfaghari Emameh, Pouria Khani, Asieh Hosseini, Johan Garssen, Reza Falak

Abstract readPublished Erratum
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The evaluation of serum magnesium and calcium/magnesium ratio in patients with breast cancer receiving adjuvant chemotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Article
  5. Advances in Atherosclerosis Theranostics Harnessing Iron Oxide-Based Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Nafiseh BehranvandImmunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Farzad NasriImmunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Reza Zolfaghari EmamehDepartment of Energy and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.ORCID http://orcid.org/0000-0002-3253-7844
Pouria KhaniDepartment of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Asieh HosseiniRazi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Johan GarssenDivision of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
Reza FalakImmunology Research Center, Iran University of Medical Sciences, Tehran, Iran. falak.r@iums.ac.ir.ORCID http://orcid.org/0000-0002-1842-2952

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34453193
PMCPMC10991480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.